ClinicalTrials.gg
RecruitingNCT06343064KYLIN-1Updated May 21, 2025

Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

A Phase 1/2 interventional study of Vebreltinib and PLB1004 in Non-Small-Cell Lung Cancer, sponsored by Avistone Biotechnology Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-21.

Sponsored by Avistone Biotechnology Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jun 2023, registered Mar 2024).
  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
156
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing andamertinib in Carcinoma, Non-Small-Cell Lung — 9 open to participants now, 10 under way, 2 of them phase 3. andamertinib · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
4th of 11
156 · median 120
Started
2023
with 2 others
Phase 1/2
3 of 11
3 open now
Registered
5th of 11
by date
Lead sponsor
8 of 11
Avistone Biotechnology Co., Ltd.

Among the 11 studies testing andamertinib in Carcinoma, Non-Small-Cell Lung, this one is the 4th largest by planned enrollment, is one of 3 that started in 2023, is one of 3 in phase 1/2, and was the 5th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

9 of the 11 studies testing andamertinib in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

About andamertinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing andamertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 in EGFR TKI Relapsed MET Amplified or MET Expression in NSCLC

Read the detailed description

Open label, multicenter Phase Ib/II clinical study to evaluate the safety, efficacy, and pharmacokinetics of Vebreltinib in combination with PLB1004 in patients with locally advanced or metastatic non-small cell lung cancer with MET overexpression or MET amplification following EGFR-TKI treatment failure.

03

Conditions studied

  • Non-Small-Cell Lung Cancer

Keywords

  • Non-Small-Cell Lung Cancer
  • EGFR
  • NSCLC
  • Lung Cancer
  • MET Amplified
  • MET Expression
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand and willingness to sign a written document.
  2. Aged at least 18 years old.
  3. or cytologically confirmed locally advanced or NSCLC (stage IIIB\~IV).
  4. EGFR mutations, including exon 19 deletion and exon 21 L858R.
  5. C-Met overexpression and/or c-Met amplification confirmed after treatment with EGFR-TKI.
  6. At least one as defined by V1.1.
  7. performance status 0 to 1.

Exclusion criteria

Exclusion Criteria:

  1. Previous treatment with MET inhibitors or HGF-targeted therapy.
  2. There are mutations of ALK or ROS1.
  3. Have symptomatic and neurologically unstable central nervous system (CNS) or CNS disease that requires increased doses for control.
  4. Pregnant or nursing women.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
156 participants (estimated)

Study arms

  • Experimental
    Phase Ib:Vebreltinib 100mg/150mg/200mg BID + PLB1004 80mg/160mg QD

    In the dose-escalation and dose-expansion phase, patients received oral Vebreltinib 100mg/150mg/200mg BID plus PLB1004 80mg/160mg once daily.

    Drug: Vebreltinib · Drug: PLB1004

  • Experimental
    Phase II:Cohort 1

    In phase II-Cohort 1:Failed first-generation or second-generation EGFR inhibitors, negative T790M mutation and c-Met amplification(GCN≥6).Patients received oral Vebreltinib(RP2D)plus PLB1004 (RP2D).

    Drug: Vebreltinib · Drug: PLB1004

  • Experimental
    Phase II:Cohort 2

    In phase II-Cohort 2 :Failed third-generation EGFR inhibitors, c-Met amplification(GCN≥6).Patients received oral Vebreltinib(RP2D)plus PLB1004 (RP2D).

    Drug: Vebreltinib · Drug: PLB1004

  • Experimental
    Phase II:Cohort 3

    In phase II-Cohort 3 :Failed first-generation or second-generation EGFR inhibitors, c-Met over expression.Patients received oral Vebreltinib(RP2D)plus PLB1004 (RP2D).

    Drug: Vebreltinib · Drug: PLB1004

Interventions

  • Phase Ib is a dose escalation study, the initial dose of Vebreltinib is 100mg/150mg/200mg,according to the result of Phase Ib, will confirm the RP2D.

    Also known as: Bozitinib, PLB1001

  • Phase Ib is a dose escalation study, the initial dose of PLB1004 is 80mg/160mg,according to the result of Phase Ib, will confirm the RP2D.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]).

    In phase Ib,Incidence of Treatment-Emergent Adverse Events (TEAEs),

    Time frame: 3 years

  2. Incidence of dose-limiting toxicities (DLT) as defined in the protocol.

    In phase Ib,Number of patients with at least 1 dose-limiting toxicity (DLT), which is any toxicity defined as a DLT in the Clinical Study Protocol

    Time frame: 28 days

  3. Overall Response Rate (ORR)

    In phase II,ORR is defined as the proportion of subjects with confirmed best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1.

    Time frame: 3 years

Secondary outcomes

  1. Pharmacokinetics of Vebreltinib and PLB1004 : Area under the concentration time curve (AUC)

    In phase Ib,Measurement of PK parameters: Area under the concentration time curve (AUC)

    Time frame: From date of first dose up until 28 days post last dose

  2. Pharmacokinetics of Vebreltinib and PLB1004: Maximum plasma concentration of the study drug (C-max)

    In phase Ib,Measurement of PK parameters: Maximum observed plasma concentration of the study drug (C-max)

    Time frame: From date of first dose up until 28 days post last dose

  3. Pharmacokinetics of Vebreltinib and PLB1004: Time to maximum plasma concentration of the study drug (T-max)

    In phase Ib,Measurement of PK parameters: Time to maximum observed plasma concentration of the study drug (T-max)

    Time frame: From date of first dose up until 28 days post last dose

  4. Incidence of Treatment-Emergent Adverse Events

    In phase II,Incidence of Treatment-Emergent Adverse Events (TEAEs),A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Dec 2026, 42 months after the start.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 42 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2024
First posted
Apr 2, 2024
StartActual
Jun 13, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06343064
Lead sponsor
Avistone Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Apr 2, 2024
Start date
Jun 13, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 21, 2025

Study contacts

Liang Lin
Contact
linliang@avistonebio.com
+86-10-84148931

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Andamertinib

Start the discussion